Summary:
The 
Introduction
Some HBe antibody (HBeAb) positive patients with chronic hepatitis B show in the serum transaminase level (Bonino et al. 1986 ). In these patients, point mutation has been observed in the pre-C and core regions of hepatitis B virus (HBV) (Carmen et al. 1989; Ehata et al. 1993) . We report an HBeAb-positive patient with chronic hepatitis B in whom a strain in the pre-C region that underwent point mutation (pre-C mutant) was demonstrated by the PCR method (Kinoshita et al. 1994) at the time of acute exacerbation, and in whom an improvement in liver function and disappearance of the pre-C mutant were observed after longterm interferon (IFN) therapy. In the peripheral blood, the leukocyte count and platelet count were slightly decreased. In the coagulation system, the prothrombin time (PT) was 81%, and the hepaplastin test (HPT) revealed 48%. The anti-HAV antibody, HCV antibody, and anti-nuclear antibody were negative. Concerning HBV markers, the HBeAg was negative and HBeAb was positive, but DNA -p was positive (827cpm). Based on these findings, a diagnosis of acute exacerbation of chronic hepatitis B was made.
Clinical course (Fig.1) After admission, PT and HPT decreased, suggesting progression to severe hepatitis. Glucagon-insulin therapy and administration of frozen plasma and Stronger Neo-Minophagen C R were initiated. The transaminase level transiently decreased but increased again on April 1 (sGOT, 744 IU; sGPT, 730 IU). The PT 
Discussion
In chronic hepatitis B, HBV-DNA decreases and hepatitis subsides with seroconversion from the presence of HBeAg to HBeAb (Hoofnagle, 1983) . However, about 10% of HBeAb-positive patients with chronic hepatitis B show persistence of virus proliferation and an abnormal transaminase level, resulting in progression of liver lesions (Bonino et al. 1986; Carmen et al. 1989) . Carmen et al. (1989) analyzed the nucleotide sequence of HBV-DNA in HBV-DNA-positive and HBeAg-negative patients with chronic hepatitis B and observed point mutation in the pre-C region from the 1896th and 1899th G (guanine) to A (adenine). They speculated that the 28th amino acid residue at the N terminal becomes a "TAG" stop codon , resulting in no secretion of HBeAg. Ehata et al. (1993) examined the nucleotide sequence of the HBV gene in patients who died of fulminant hepatitis B or acute exacerbation of chronic hepatitis and observed a high incidence of mutation in the core and pre-C region. These findings suggest that pre-C mutation is involved in the development of fulminant hepatitis B and acute exacerbation of BeAb-positive type chronic hepatitis. In our patient, a pre-C mutant was detected during the same period as observation of an increase in the transaminase level. This mutant disappeared after normalization of the transaminase level. The following two possible mechanisms have been suggested for liver cell injury by pre-C mutants.
(1) Marked immune responses occur against HBcAg expressed on the liver cell surface after disappearance of HBeAg. (2) An in vitro experiment showed a marked increase in the production of HBeAg in the presence of a pre-C mutant, suggesting that pre-C mutants are cytotoxic (Imazeki et al. 1992 ). However, a recent study showed the presence of pre-C mutants in asymptomatic carriers also (Tur Kaspa et al. 1992 ). This suggests the involvement of regions other than the pre-C region in the pathology of chronic hepatitis B. Ehata et al. examined the nucleotide sequence of the genes in the pre-C and core regions in patients with chronic hepatitis B (Ehata et al. 1992) and patients who died of fulminant hepatitis or acute exacerbation of chronic hepatitis B (Ehata et al. 1993) . They reported the presence of mutations in the core region in a high percentage of patients with chronic hepatitis B showing advanced histological findings of the liver, all patients who died of fulminant hepatitis or acute exacerbation of chronic hepatitis B, and all HBeAbpositive patients with chronic hepatitis showing pre-C mutants. In addition, they serially evaluated patients showing seroconversion from the presence of HBeAg to HBeAb and observed mutation first in the core region and then in the pre-C region (Ehata et al. 1992 ). These results suggest that mutation in the core region is also involved in acute exacerbation in HBeAb-positive patients with chronic hepatitis. In our patient, it is possible that mutation occurred not only in the pre-C region but also in the core region. 
